What You Should Know
- The Launch: Maven Clinic, previously known for its massive enterprise footprint, has opened the beta waitlist for its new direct-to-consumer (DTC) platform, making its virtual care model available to women nationwide regardless of employer coverage.
- The Market Context: For the last decade, Maven focused primarily on B2B partnerships, securing over 2,300 employer and health plan clients and covering 28 million lives.
- The Clinical Pillars: The DTC platform features three core offerings:
- Virtual Care: Access to over 30 specialties, including OB-GYNs, mental health providers, lactation consultants, and doulas.
- Women-Centric GLP-1 Care: Access to FDA-approved weight-loss medications with prescribing decisions that factor in reproductive history (like PCOS, postpartum, and perimenopause), rather than relying strictly on BMI.
- Comprehensive Hormone Care: Specialized support and personalized treatment plans for the perimenopause and menopause transitions.
- The Enterprise Loop: The consumer platform is designed to ultimately feed back into Maven’s B2B ecosystem. Employers and health plans will be able to add these specific consumer offerings for their members starting in 2027.
Curing “App Fatigue”
The DTC launch is strategically timed to capitalize on a deeply fragmented consumer market. The boom in telehealth has created a disjointed reality for the average patient: one app for a GLP-1 prescription, a different startup for menopause hormone therapy, and a traditional, brick-and-mortar OB-GYN for annual exams.
Maven is positioning itself as the unified alternative. The platform connects patients with over 30 specialties—ranging from pediatricians to physical therapists—allowing a woman’s medical context to build over time rather than resetting with every new login. A fertility consultation can seamlessly inform a pregnancy plan, which later links directly to postpartum and hormone care.
“Women have more ways to manage their health today than ever before — and less coherence than ever before,” said Kate Ryder, founder and CEO of Maven Clinic. “Today we’re bringing that model directly to women everywhere — trusted providers, integrated care, and a clear point of view on what women need.”
A Calculated GLP-1 Strategy
Maven’s entry into the explosive GLP-1 weight-loss market is particularly notable for how it contrasts with existing DTC telehealth giants. While many platforms operate as high-volume transactional pipelines for semaglutide, Maven is anchoring its GLP-1 prescribing entirely around female reproductive health. Treatment decisions are guided by a clinician who evaluates factors like PCOS, postpartum recovery, perimenopause, and future fertility plans, rather than utilizing a simple BMI checkout screen. Furthermore, the program pairs the medication with strict nutrition and strength guidance to preserve muscle mass.The beta waitlist opens today.
Learn more at https://www.mavenclinic.com/lp/early-access
